PAMPs and DAMPs as triggers for DIC

被引：108

作者：

Ito T. ^{[1
,2
]}

机构：

[1] Department of Emergency and Critical Care Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima

[2] Department of Systems Biology in Thromboregulation, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima

来源：

Journal of Intensive Care | / 2卷 / 1期

基金：

日本学术振兴会;

关键词：

Damage-associated molecular patterns (DAMPs); Disseminated intravascular coagulation (DIC); Immunothrombosis; Neutrophil extracellular traps (NETs); Pathogen-associated molecular patterns (PAMPs); Tissue factor;

D O I：

10.1186/s40560-014-0065-0

中图分类号：

学科分类号：

摘要：

Thrombosis is generally considered harmful because it compromises the blood supply to organs. However, recent studies have suggested that thrombosis under certain circumstances plays a major physiological role in early immune defense against invading pathogens. This defensive role of thrombosis is now referred to as immunothrombosis. Activated monocytes and neutrophils are two major inducers of immunothrombosis. Monocytes and neutrophils are activated when they detect pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). Detection of PAMPs and DAMPs triggers tissue factor expression on monocytes and neutrophil extracellular trap (NET) release by neutrophils, promoting immunothrombosis. Although tissue factor-mediated and NET-mediated immunothrombosis plays a role in early host defense against bacterial dissemination, uncontrolled immunothrombosis may lead to disseminated intravascular coagulation. © 2014 Ito; licensee BioMed Central Ltd.

引用

共 100 条

[91]

Conway, E.M., Van de Wouwer, M., Pollefeyt, S., Jurk, K., Van Aken, H., De Vriese, A., Weitz, J.I., Theilmeier, G., The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways (2002) J Exp Med, 196, pp. 565-577. , 2193995, 12208873

[92]

Saito, H., Maruyama, I., Shimazaki, S., Yamamoto, Y., Aikawa, N., Ohno, R., Hirayama, A., Aoki, N., Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial (2007) J Thromb Haemost, 5, pp. 31-41. , 17059423

[93]

Ogawa, Y., Yamakawa, K., Ogura, H., Kiguchi, T., Mohri, T., Nakamori, Y., Kuwagata, Y., Fujimi, S., Recombinant human soluble thrombomodulin improves mortality and respiratory dysfunction in patients with severe sepsis (2012) J Trauma Acute Care Surg, 72, pp. 1150-1157

[94]

Yamakawa, K., Fujimi, S., Mohri, T., Matsuda, H., Nakamori, Y., Hirose, T., Tasaki, O., Shimazu, T., Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study (2011) Crit Care, 15. , 3218981, 21569368

[95]

Yamakawa, K., Ogura, H., Fujimi, S., Morikawa, M., Ogawa, Y., Mohri, T., Nakamori, Y., Shimazu, T., Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis (2013) Intensive Care Med, 39, pp. 644-652. , 3607733, 23361628

[96]

Vincent, J.L., Ramesh, M.K., Ernest, D., Larosa, S.P., Pachl, J., Aikawa, N., Hoste, E., Kaul, I., A randomized, double-blind, placebo-controlled, phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation (2013) Crit Care Med, 41, pp. 2069-2079. , 23979365

[97]

Hoffmann, J.N., Vollmar, B., Laschke, M.W., Inthorn, D., Kaneider, N.C., Dunzendorfer, S., Wiedermann, C.J., Menger, M.D., Adverse effect of heparin on antithrombin action during endotoxemia: microhemodynamic and cellular mechanisms (2002) Thromb Haemost, 88, pp. 242-252

[98]

Warren, B.L., Eid, A., Singer, P., Pillay, S.S., Carl, P., Novak, I., Chalupa, P., Opal, S.M., Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial (2001) JAMA, 286, pp. 1869-1878. , 11597289

[99]

Kienast, J., Juers, M., Wiedermann, C.J., Hoffmann, J.N., Ostermann, H., Strauss, R., Keinecke, H.O., Opal, S.M., Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation (2006) J Thromb Haemost, 4, pp. 90-97. , 16409457

[100]

Wiedermann, C.J., Hoffmann, J.N., Juers, M., Ostermann, H., Kienast, J., Briegel, J., Strauss, R., Opal, S.M., High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety (2006) Crit Care Med, 34, pp. 285-292. , 16424704

← 1 2 3 4 5 6 7 8 9 10 →